Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Irbesartan Intermediates: Irbesartan CAS 138402-11-6 Cyano-Irbesartan CAS 138401-24-8 Trityl Irbesartan CAS 138402-10-5 TTBB CAS 124750-51-2 Irbesartan Side Chain Hydrochloride CAS 151257-01-1| Item | Specifications |
| Appearance | White to Almost White Powder |
| Purity / Analysis Method | >96.0% (HPLC) |
| Loss on Drying | <0.50% |
| Impurity A | <2.00% (HPLC) 5-(4-Methyl-1,1-Biphenyl-2-yl)-1-Triphenylmethyl-1H-Tetrazole |
| Impurity B | <2.00% 5-(4'.4'-Dibromomethyl-1,1-Biphenyl-2-yl)-1-Triphenylmethyl-1H-Tetrazole |
| Infrared Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Irbesartan (CAS: 138402-11-6); Olmesartan Medoxomil Impurity |
Description:
Specifications:
Package & Storage:
| Chemical Name | 5-(4'-Bromomethyl-1,1'-Biphenyl-2-yl)-1-Triphenylmethyl-1H-Tetrazole |
| Synonyms | TTBB; BBTT; 5-[4'-Bromomethyl-(1,1'-Biphenyl)-2-yl]-1-Triphenylmethyltetrazole; N-(Triphenylmethyl)-5-(4'-Bromomethylbiphenyl-2-yl-)tetrazole; Olmesartan Impurity 12; Losartan Bromo N1-Trityl Impurity |
| CAS Number | 124750-51-2 |
| CAT Number | RF-PI1878 |
| Stock Status | In Stock, Production Capacity 150MT/Year |
| Molecular Formula | C33H25BrN4 |
| Molecular Weight | 557.48 |
| Melting Point | 152.0~155.0℃ |
| Density | 1.28±0.10 g/cm3 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
5-(4'-Bromomethyl-1,1'-Biphenyl-2-yl)-1-Triphenylmethyl-1H-Tetrazole (TTBB) (CAS: 124750-51-2) is an intermediate of Irbesartan (CAS: 138402-11-6). Irbesartan is used for the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Irbesartan is also used as a second line agent in the treatment of conges. Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. It was developed by Sanofi Research (now part of Sanofi-Aventis). It is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.
